Henry Schein, Inc. (HSIC) vs Vaxcyte, Inc. (PCVX)
A side-by-side comparison of Henry Schein, Inc. and Vaxcyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HSIC
Henry Schein, Inc.
$84.72HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
PCVX
Vaxcyte, Inc.
$64.67HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — HSIC vs PCVX
growth of $100 · dividends reinvested · last 6yHSIC +25.8% (+3.9%/yr)PCVX +182.3% (+18.9%/yr)PCVX compounded faster over this window
HSIC PCVX
HSIC vs PCVX: by the numbers
- •HSIC is the larger company ($9.65B vs $9.34B market cap).
- •HSIC is profitable (2.96% net margin) while PCVX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | HSIC | PCVX |
|---|---|---|
| P/E ratio | 24.70 | N/A |
| Forward P/E | 15.73 | N/A |
| PEG ratio | 7.82 | N/A |
| P/S ratio | 0.71 | N/A |
| P/B ratio | 3.06 | 3.39 |
| EV / EBITDA | 12.24 | N/A |
| FCF yield | 5.58% | N/A |
Profitability
| Metric | HSIC | PCVX |
|---|---|---|
| Gross margin | 30.31% | 0.00% |
| Operating margin | 5.69% | 0.00% |
| Net margin | 2.96% | 0.00% |
| ROE | 12.77% | -38.59% |
| ROIC | 6.53% | -40.65% |
Growth (annualized)
| Metric | HSIC | PCVX |
|---|---|---|
| Revenue CAGR (5Y) | 2.71% | N/A |
| EPS CAGR (5Y) | 3.14% | N/A |
| FCF CAGR (5Y) | 0.82% | N/A |
| Total return CAGR (5Y) | 1.39% | 25.08% |
Frequently asked
- Is HSIC or PCVX more profitable?
- HSIC runs the higher net margin — HSIC at 2.96% versus PCVX at 0.00%.
- How have HSIC and PCVX total returns compared?
- Over the past 5 years, HSIC delivered 1.39% and PCVX delivered 25.08% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Henry Schein P/E ratioHenry Schein ROEVaxcyte ROEHenry Schein operating marginVaxcyte operating marginHenry Schein revenue growthVaxcyte revenue growthHenry Schein free cash flowVaxcyte free cash flow
Henry Schein & Vaxcyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.